Dr. Quay speaks with Fox News about origin of COVID-19

As we enter the new year, ongoing efforts to understand and combat COVID-19 persist, with researchers uncovering new insights into the virus’s origins.

Dr. Quay discusses recent findings regarding the initial spread of the virus, highlighting a genetic cluster identified in patients from a military hospital in Wuhan, China, suggesting transmission within a confined group.

By tracing the movement of patients to nearby subway stations and ultimately to the airport, Dr. Quay suggests Line Two of Wuhan’s subway system as a crucial transmission route. This information not only sheds light on the virus’s early spread but also aids in predicting its future mutations, guiding the development of effective therapeutics.

As debates persist regarding whether the virus originated in a seafood market or a laboratory, ongoing research aims to provide clarity in the coming months.

Read the full article on Fox News 26 Houston.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies

Dr. Steven Quay investigates COVID-19's origins, analyzing evidence that suggests SARS-CoV-2 may have resulted from a lab incident rather than natural transmission. Through statistical methods, Dr. Quay estimates a 98% probability of a lab origin, challenging popular theories about animal-to-human transmission and highlighting possible lab safety issues in Wuhan. In this video, he also emphasizes the importance of global safety regulations to prevent future pandemics. Watch to uncover key insights on COVID-19's origins and why lab safety matters for global health.

This video describes the clinical data from the Atossa Therapeutics press release of October 31, 2024 entitled, Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer